A pilot phase 2 trial is assessing the safety and efficacy of IV DNase 1 in AIS patients receiving IV tPA and eligible for EVT (NETs-TARGET study, ClinicalTrials.gov: NCT04785066). Here, PLAT is linked to androgen insensitivity syndrome.